Combination Lipid Therapy in Type 2 Diabetes
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Modification of triglycerides with the proliferator activated receptor-alpha agonist fenofibrate failed to reduce ASCVD events in 2 separate trials in persons with T2D: (Fenofibrate Intervention and Event Lowering in Diabetes [FIELD]377 and ACCORD-Lipid),367 although the mean baseline triglyceride levels were 153 mg/dL in FIELD377 and 162 mg/dL in ACCORD-Lipid.367”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [377]
In the citing paper
“Yet, subgroup analyses have strongly suggested that patients with high triglyceride and low high-density lipoprotein (HDL) cholesterol levels might derive substantial clinical benefit from decreased triglyceride levels, particularly if they have concomitant type 2 diabetes. 7,8”
From Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk (2022) · cites this paper as [7]
In the citing paper
“the significant reduction of CV event risk was shown for each test, particularly in the post-hoc analysis of the subclasses of patients with or without statin who had atherogenic dyslipidemia (high serum TG and low HDL-C levels) [12].”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [12]
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Brown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Manninen, V, Tenkanen, L., Koskinen, P., Huttunen, J. K., Mänttäri, M., Heinonen, O. P., & Frick, M. H. (1992) · Circulation · doi:10.1161/01.cir.85.1.37 · Cited by 1,329
Robins, S. J., Collins, D., Wittes, J. T., Papademetriou, V., Deedwania, P. C., Schaefer, E. J., McNamara, J. R., Kashyap, M. L., Hershman, J. M., Wexler, L. F., et al. (2001) · JAMA · doi:10.1001/jama.285.12.1585 · Cited by 921
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies
(2010) · The Lancet · doi:10.1016/s0140-6736(10)60545-4 · Cited by 716
Rubins, H. B. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.22.2597 · Cited by 586
Research works printed but not linked: 2
- 10.1001/jama.2009.1619 · DOI · Paper page
- 10.1056/NEJMoa1001282 · DOI · Paper page
Cited by
Libby, P., Buring, J. E., Badimon, L., Hansson, G. K., Deanfield, J., Bittencourt, M. S., Tokgözoğlu, L., & Lewis, E. F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0106-z · Cited by 3,211
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I
Paneni, F., Beckman, J. A., Creager, M. A., & Cosentino, F. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht149 · Cited by 1,401
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2016) · Endocrine Practice · doi:10.4158/ep151126.cs · Cited by 878
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.02.003 · Cited by 773
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
Das Pradhan, A., Glynn, R. J., Fruchart, J.-C., MacFadyen, J. G., Zaharris, E. S., Everett, B. M., Campbell, S. E., Oshima, R., Amarenco, P., Blom, D. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2210645 · Cited by 749
Hegele, R. A., Ginsberg, H. N., Chapman, M. J., Nordestgaard, B. G., Kuivenhoven, J. A., Averna, M., Borén, J., Bruckert, E., Catapano, A. L., Descamps, O. S., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70191-8 · Cited by 635
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Sandesara, P. B., Virani, S. S., Fazio, S., & Shapiro, M. D. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00184 · Cited by 608
Garber, A. J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bush, M. A., DeFronzo, R. A., Garber, J. R., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2019-0472 · Cited by 598
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2018) · Endocrine Practice · doi:10.4158/cs-2017-0153 · Cited by 502
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.07.007 · Cited by 462
Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II
Beckman, J. A., Paneni, F., Cosentino, F., & Creager, M. A. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht142 · Cited by 434
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2017) · Endocrine Practice · doi:10.4158/ep161682.cs · Cited by 435
Hypertriglyceridaemia and risk of coronary artery disease
Reiner, Ž. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.31 · Cited by 387
Athyros, V. G., Doumas, M., Imprialos, K. P., Stavropoulos, K., Georgianou, E., Katsimardou, A., & Karagiannis, A. (2018) · Hormones · doi:10.1007/s42000-018-0014-8 · Cited by 367
The Role of Triglycerides in Atherosclerosis
Talayero, B. G., & Sacks, F. M. (2011) · Current Cardiology Reports · doi:10.1007/s11886-011-0220-3 · Cited by 355
High-density lipoproteins: A consensus statement from the National Lipid Association
Toth, P. P., Barter, P. J., Rosenson, R. S., Boden, W. E., Chapman, M. J., Cuchel, M., D'Agostino, R. B., Davidson, M. H., Davidson, W. S., Heinecke, J. W., et al. (2013) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.08.001 · Cited by 336
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2019) · Endocrine Practice · doi:10.4158/cs-2018-0535 · Cited by 297
“Subgroup analyses and meta-analyses of major fibrate trials, however, have shown a relative risk reduction for ASCVD events of 26 to 35% among patients with moderate dyslipidemia (triglycerides >200 mg/dL and HDL-C <40 mg/dL) (153-158).”
BackgroundVarbo, A., Benn, M., & Nordestgaard, B. G. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.11.008 · Cited by 251
“However, these trials mainly focused on elevated LDL cholesterol levels or reduced HDL cholesterol levels, and a meta-analysis of post-hoc analyses from several fibrate trials of subgroups of patients with elevated triglyceride levels, showed a large benefit of fibrates on risk of cardiovascular disease in these patie…”
ResultManagement of hypertriglyceridemia
Simha, V. (2020) · BMJ · doi:10.1136/bmj.m3109 · Cited by 223
From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk
Shapiro, M. D., & Fazio, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306471 · Cited by 217
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., Davidson, M. B., Einhorn, D., Garvey, W. T., et al. (2013) · Endocrine Practice · doi:10.4158/ep13176.csuppl · Cited by 220
2018 Guidelines for the management of dyslipidemia
Rhee, E.-J., Kim, H. C., Kim, J. H., Lee, E. Y., Kim, B. J., Kim, E. M., Song, Y., Lim, J. H., Kim, H. J., Choi, S., et al. (2019) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2019.188 · Cited by 213
Xiao, C., Dash, S., Morgantini, C., Hegele, R. A., & Lewis, G. F. (2016) · Diabetes · doi:10.2337/db16-0046 · Cited by 212
Optimizing cholesterol treatment in patients with muscle complaints
Rosenson, R. S., Baker, S., Banach, M., Borow, K. M., Braun, L. T., Bruckert, E., Brunham, L. R., Catapano, A. L., Elam, M. B., Mancini, G. B. J., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.07.752 · Cited by 193
2018 Guidelines for the Management of Dyslipidemia in Korea
Rhee, E.-J., Kim, H. C., Kim, J. H., Lee, E. Y., Kim, B. J., Kim, E. M., Song, Y., Lim, J. H., Kim, H. J., Choi, S., et al. (2019) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2019.8.2.78 · Cited by 192
Yamashita, S., Masuda, D., & Matsuzawa, Y. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-0823-5 · Cited by 191
Contribution of remnant cholesterol to cardiovascular risk
Langsted, A., Madsen, C. M., & Nordestgaard, B. G. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13059 · Cited by 189
Fruchart, J.-C. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-82 · Cited by 189
Vallejo-Vaz, A. J., Fayyad, R., Boekholdt, S. M., Hovingh, G. K., Kastelein, J. J., Melamed, S., Barter, P., Waters, D. D., & Ray, K. K. (2018) · Circulation · doi:10.1161/circulationaha.117.032318 · Cited by 187
Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor
Tenenbaum, A., Klempfner, R., & Fisman, E. Z. (2014) · Cardiovascular Diabetology · doi:10.1186/preaccept-2085133501150912 · Cited by 186
Residual macrovascular risk in 2013: what have we learned?
(R3i), F. T. R. R. R. I., Fruchart, J.-C., Davignon, J., Hermans, M. P., Al-Rubeaan, K., Amarenco, P., Assmann, G., Barter, P., Betteridge, J., Bruckert, E., et al. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-26 · Cited by 172
Tenenbaum, A., & Fisman, E. Z. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-125 · Cited by 166
Serum triglycerides and risk of cardiovascular disease
Boullart, A. C. I., Graaf, J. D., & Stalenhoef, A. F. H. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.002 · Cited by 188
Reiner, Ž. (2013) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2013.05.002 · Cited by 147
Varbo, A., & Nordestgaard, B. G. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308305 · Cited by 158
Fruchart, J.-C. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0602-y · Cited by 141
Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0864-7 · Cited by 140
Averna, M., Banach, M., Bruckert, E., Drexel, H., Farnier, M., Gaita, D., Magni, P., März, W., Masana, L., Mello e Silva, A., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.03.039 · Cited by 137
Self-citationArai, H., Yamashita, S., Yokote, K., Araki, E., Suganami, H., & Ishibashi, S. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.03.032 · Cited by 124
Rosenzweig, J. L., Bakris, G. L., Berglund, L. F., Hivert, M.-F., Horton, E. S., Kalyani, R. R., Murad, M. H., & Vergès, B. L. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-01338 · Cited by 126
Everett, B. M., Cook, N. R., Magnone, M. C., Bobadilla, M., Kim, E., Rifai, N., Ridker, P. M., & Pradhan, A. D. (2011) · Circulation · doi:10.1161/circulationaha.110.009928 · Cited by 117
Demystifying the management of hypertriglyceridaemia
Watts, G. F., Ooi, E. M. M., & Chan, D. C. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.140 · Cited by 115
Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy
Wang, L., Cai, Y., Jian, L., Cheung, C. W., Zhang, L., & Xia, Z. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01188-0 · Cited by 121
Atherogenic Dyslipidemia and Residual Cardiovascular Risk in Statin-Treated Patients
Sirimarco, G., Labreuche, J., Bruckert, E., Goldstein, L. B., Fox, K. M., Rothwell, P. M., Amarenco, P., Bousser, M.-G., Chamorro, A., Ford, I., et al. (2014) · Stroke · doi:10.1161/strokeaha.113.004229 · Cited by 106
Orringer, C. E., Jacobson, T. A., & Maki, K. C. (2019) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2019.10.014 · Cited by 103
Ray, K. K., Leiter, L. A., Müller‐Wieland, D., Cariou, B., Colhoun, H. M., Henry, R. R., Tinahones, F. J., Bujas‐Bobanovic, M., Domenger, C., Letierce, A., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13257 · Cited by 102
Ferrari, R., Aguiar, C., Alegria, E., Bonadonna, R. C., Cosentino, F., Elisaf, M., Farnier, M., Ferrières, J., Filardi, P. P., Hancu, N., et al. (2016) · European Heart Journal Supplements · doi:10.1093/eurheartj/suw009 · Cited by 97
KONES, R. J. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s37119 · Cited by 105
A brief elevation of serum amyloid A is sufficient to increase atherosclerosis
Thompson, J. C., Jayne, C., Thompson, J., Wilson, P. G., Yoder, M. H., Webb, N. R., & Tannock, L. R. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m054015 · Cited by 95
Dyslipidemia Management in Adults With Diabetes
Lazarte, J., & Hegele, R. A. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.07.003 · Cited by 99
Aguíar, C., Alegría, E., Bonadonna, R. C., Catapano, A. L., Cosentino, F., Elisaf, M., Farnier, M., Ferrières, J., Filardi, P. P., Hâncu, N., et al. (2015) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(15)30001-5 · Cited by 91
Maki, K. C., Bays, H. E., & Dicklin, M. R. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.04.003 · Cited by 83
Consensus statement on management of dyslipidemia in Indian subjects
Chandra, K. S., Bansal, M., Nair, T., Iyengar, S. S., Gupta, R., Manchanda, S. C., Mohanan, P. P., Rao, V. D., Manjunath, C. N., Sawhney, J. P. S., et al. (2014) · Indian Heart Journal · doi:10.1016/j.ihj.2014.12.001 · Cited by 102
A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations
Ling (2013) · Cardiology Research · doi:10.4021/cr270w · Cited by 126
Stahel, P., Xiao, C., Hegele, R. A., & Lewis, G. F. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.12.007 · Cited by 75
Saroglitazar for the treatment of dyslipidemia in diabetic patients
Joshi, S. R. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1009894 · Cited by 79
Lamprea-Montealegre, J. A., Staplin, N., Herrington, W. G., Haynes, R., Emberson, J., Baigent, C., de Boer, I. H., & on behalf of the SHARP Collaborative Group (2019) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07320619 · Cited by 84
Lawler, P. R., Akinkuolie, A. O., Harada, P., Glynn, R. J., Chasman, D. I., Ridker, P. M., & Mora, S. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.007402 · Cited by 69
Valensi, P. E., Avignon, A., Sultan, A., Chanu, B., Nguyen, M. T., & Cosson, E. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0415-4 · Cited by 75
Lipid-lowering in diabetes: An update
Chait, A., Eckel, R. H., Vrablík, M., & Zambon, A. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117313 · Cited by 81
Yamashita, S., Masuda, D., & Matsuzawa, Y. (2019) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.48918 · Cited by 66
Maki, K. C., Guyton, J. R., Orringer, C. E., Hamilton-Craig, I., Alexander, D. D., & Davidson, M. H. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2016.03.008 · Cited by 62
Hypertriglyceridemia and Cardiovascular Diseases: Revisited
Han, S. H., Nicholls, S. J., Sakuma, I., Zhao, D. H., & Koh, K. K. (2016) · Korean Circulation Journal · doi:10.4070/kcj.2016.46.2.135 · Cited by 70
Rice, H. B., Bernasconi, A., Maki, K. C., Harris, W. S., von Schacky, C., & Calder, P. C. (2016) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2016.01.003 · Cited by 56
Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective
Elam, M., Lovato, L. C., & Ginsberg, H. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328341a5a8 · Cited by 56
PPAR-α agonists are still on the rise: an update on clinical and experimental findings
Ferri, N., Corsini, A., Sirtori, C., & Ruscica, M. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1312339 · Cited by 55
Triglycerides, Atherosclerosis, and Cardiovascular Outcome Studies: Focus on Omega-3 Fatty Acids
Handelsman, Y., & Shapiro, M. D. (2016) · Endocrine Practice · doi:10.4158/ep161445.ra · Cited by 60
Yamashita, S., Arai, H., Yokote, K., Araki, E., Suganami, H., & Ishibashi, S. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2018.06.010 · Cited by 51
Valensi, P. E., Henry, P., Boccara, F., Cosson, E., Prévost, G., Emmerich, J., Ernande, L., Marcadet, D. M., Mousseaux, É., Rouzet, F., et al. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.08.002 · Cited by 62
Triglyceride and cardiovascular risk: A critical appraisal
Singh, A. K., & Singh, R. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.183460 · Cited by 51
López-Jiménez, F. A., Simha, V., Thomas, R. J., Allison, T. G., Basu, A., Fernandes, R., Hurst, R. T., Kopecky, S. L., Kullo, I. J., Mulvagh, S. L., et al. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.06.016 · Cited by 49
Atherogenic Dyslipidemia and Residual Vascular Risk After Stroke or Transient Ischemic Attack
Hoshino, T., Ishizuka, K., Toi, S., Mizuno, T., Nishimura, A., Takahashi, S., Wako, S., & Kitagawa, K. (2021) · Stroke · doi:10.1161/strokeaha.121.034593 · Cited by 49
Shetty, S., Kumar, S., Mathur, R. P., Sharma, K. H., & Jaiswal, A. D. (2015) · Indian Heart Journal · doi:10.1016/j.ihj.2015.02.007 · Cited by 48
Morieri, M. L., Shah, H., Sjaarda, J., Lenzini, P. A., Campbell, H., Motsinger‐Reif, A. A., Gao, H., Lovato, L., Prudente, S., Pandolfi, A., et al. (2020) · Diabetes · doi:10.2337/db19-0973 · Cited by 46
for the BIP Study Group, Arbel, Y., Klempfner, R., Erez, A., Goldenberg, I., Benzekry, S., Shlomo, N., Fisman, E. Z., & Tenenbaum, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0332-6 · Cited by 40
The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia
Chan, D. C., Barrett, P. H. R., & Watts, G. F. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.10.001 · Cited by 50
Chen, A., & Tseng, C. (2013) · The Review of Diabetic Studies · doi:10.1900/rds.2013.10.101 · Cited by 38
Lipids, lipid-lowering therapy and diabetes complications
Valensi, P. E., & Picard, S. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.10.001 · Cited by 38
Agouridis, A. P., Rizos, C. V., Elisaf, M., & Filippatos, T. D. (2013) · The Review of Diabetic Studies · doi:10.1900/rds.2013.10.171 · Cited by 37
Omega-3 Fatty Acids in Arterial Hypertension: Is There Any Good News?
Brosolo, G., Porto, A. D., Marcante, S., Picci, A., Capilupi, F., Capilupi, P., Bertin, N., Vivarelli, C., Bulfone, L., Vacca, A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119520 · Cited by 48
von Eckardstein, A., & Rohrer, L. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000294 · Cited by 33
Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects
Mijares, A. H., Ascaso, J. F., Blasco, M., Brea, Á., Díaz, Á., Mantilla, T., Pedro‐Botet, J., Pintó, X., & Millán, J. (2019) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2019.02.002 · Cited by 37
Consenso de expertos sobre propuestas para la mejora del manejo de la dislipemia aterogénica
Núñez-Cortés, J. M., Pedro‐Botet, J., Brea-Hernando, Á., Rodríguez, Á. D., González‐Santos, P., Hernández‐Mijares, A., Mantilla, T., Pintó, X., & Simó, R. (2013) · Revista Española de Cardiología · doi:10.1016/j.recesp.2013.06.014 · Cited by 34
Feingold, K. R., & Grünfeld, C. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_14 · Cited by 51
Gonna, H., & Ray, K. K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13691 · Cited by 33
Pharmacological management of diabetic dyslipidemia
Filippatos, T. D., Florentin, M., Georgoula, M., & Elisaf, M. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1263565 · Cited by 33
Fruchart, J., Hermans, M. P., Fruchart‐Najib, J., & Kodama, T. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00897-x · Cited by 30
Tenenbaum, A., Medvedofsky, D. A., Fisman, E. Z., Bubyr, L., Matetzky, S., Tanné, D., Klempfner, R., Shemesh, J., & Goldenberg, I. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035298 · Cited by 26
Hypertriglyceridemia in Diabetes Mellitus: Implications for Pediatric Care
Hartz, J. C., de Ferranti, S. D., & Gidding, S. S. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00079 · Cited by 32
“However, in ACCORD, fibrates reducedCVD events in the subgroup with triglyceride levels greater than 204 mg/dL and HDL-C less than 35mg/dL [80, 81].”
BackgroundGulizia, M. M., Colivicchi, F., Ricciardi, G., Giampaoli, S., Maggioni, A. P., Averna, M. R., Graziani, M. S., Ceriotti, F., Mugelli, A., Rossi, F., et al. (2017) · European Heart Journal Supplements · doi:10.1093/eurheartj/sux029 · Cited by 27
Residual cardiovascular risk among people with diabetes
Dash, S., & Leiter, L. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13646 · Cited by 27
Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia
Filippatos, T. D., & Elisaf, M. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.593509 · Cited by 26
Management of Dyslipidemias in the Presence of the Metabolic Syndrome or Type 2 Diabetes
Matikainen, N., & Taskinen, M. (2012) · Current Cardiology Reports · doi:10.1007/s11886-012-0309-3 · Cited by 27
Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs
KONES, R. J., & Rumana, U. (2015) · Drugs · doi:10.1007/s40265-015-0429-3 · Cited by 27
Metadata
- Authors
- Saely, C. H., Rein, P., & Drexel, H.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-08-12
- Volume
- 363
- Issue
- 7
- Pages
- 692-695
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1519335354
- Cited by
- 245
- References
- 12
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 9 · 2023: 12 · 2022: 10 · 2021: 6 · 2020: 17 · 2019: 19 · 2018: 17 · 2017: 23 · 2016: 28 · 2015: 20 · 2014: 14 · 2013: 21 · 2012: 17
- FWCI
- 20.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, lipid-lowering therapy, hypertriglyceridemia, dyslipidemia, cardiovascular risk
- MeSH terms
- Hypolipidemic Agents, Coronary Artery Disease, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Humans, Cholesterol, HDL, Male, Fenofibrate, Risk, Triglycerides, Hypertriglyceridemia, Proportional Hazards Models, Simvastatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.